Verve deepens partnership with Lilly on gene editing therapies for CVD

31 Oct 2023
firstwordpharma.com
Gene TherapyLicense out/in
Verve Therapeutics, a clinical-stage biotechnology company specialising in single-course gene editing therapies for cardiovascular disease (CVD), announced Tuesday an expanded partnership with Eli Lilly.
The collaboration involves Lilly acquiring certain product rights from Beam Therapeutics related to Verve's cardiovascular in vivo gene editing programmes targeting PCSK9 and ANGPTL3, as well as an undisclosed third CVD target.
Verve's PCSK9 candidates, VERVE-101 and VERVE-102, along with the ANGPTL3 candidate, VERVE-201, aim to significantly and durably reduce low-density lipoprotein cholesterol, addressing the prevalent atherosclerotic cardiovascular disease (ASCVD).
Details of the tripartite deal
Under the terms of the expanded partnership, Lilly now holds product rights for PCSK9 and ANGPTL3 with the option to share 33% of worldwide development expenses and jointly commercialise in the US on a 50/50 basis. Verve retains all product rights outside the US and maintains control over development and commercialisation. Additionally, Lilly acquires the right to opt-in for a third undisclosed CVD target.
Verve CEO Sekar Kathiresan said "we are thrilled to gain Lilly as a potential long-term partner for the next stage of development of our gene editing medicines for people with ASCVD." He highlighted Lilly's expertise in the cardiometabolic space and their substantial investment as a testament to confidence in Verve's programmes.
Ruth Gimeno, Lilly’s group vice president, emphasised the significance of gene editing in medicine and praised Verve's leadership in cardiovascular gene editing therapies. "We are pleased to expand our relationship with Verve to develop much needed new treatment options for people with cardiovascular disease," she remarked.
Under the agreement with Lilly, Beam will receive a $200 million upfront payment and a $50 million equity investment. Additionally, Beam has the potential to receive up to $350 million in future development-stage payments, contingent on the accomplishment of specified clinical, regulatory, and alliance milestones, bringing the total potential deal consideration to $600 million.
Beam CEO John Evans lauded strategic execution of their collaboration with Verve and the latest transaction with Lilly, emphasising that the meaningful upfront capital will accelerate the advancement of their clinical and research-stage programs.
Earlier in June, Verve and Lilly entered an exclusive research collaboration to advance Verve's preclinical in vivo gene editing programme targeting lipoprotein(a).
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.